Defence Therapeutics to Build ADC Drug Delivery Powerhouse Using Its Proprietary Accum Technology
Defence Therapeutics (OTCQB: DTCFF) announced a strategic shift to supply its proprietary Accum drug‑delivery platform to antibody‑drug conjugate (ADC) developers after presenting at the World ADC Conference and CPHI.
Defence reported completed preclinical studies showing Accum‑conjugated Kadcyla produced ~20‑fold higher anti‑tumor efficacy than Kadcyla alone at the same 0.5 mg/kg dose in JIMT‑1 HER2+ mouse xenografts, with a near‑complete response in 90% of mice.
The company is engaging ADC partners to license or supply Accum for improving potency and reducing toxicity across ADC programs.
Defence Therapeutics (OTCQB: DTCFF) annuncia un cambiamento strategico per fornire la sua piattaforma proprietaria di rilascio del farmaco Accum agli sviluppatori di coniugati anticorpo-farmaco (ADC) dopo aver partecipato alla World ADC Conference e al CPHI.
Defence ha riferito di aver completato studi preclinici che mostrano che l'Accum-coniugato Kadcyla ha prodotto circa un'efficacia antitumorale 20 volte superiore a Kadcyla da solo alla stessa dose di 0,5 mg/kg in xenograft di topi JIMT-1 HER2+, con una risposta quasi completa nel 90% dei topi.
L'azienda sta collaborando con partner ADC per concedere in licenza o fornire Accum al fine di migliorare la potenza e ridurre la tossicità nei programmi ADC.
Defence Therapeutics (OTCQB: DTCFF) anunció un cambio estratégico para suministrar su plataforma propietaria de entrega de fármacos Accum a desarrolladores de conjugados anticuerpo-fármaco (ADC) tras su presentación en la World ADC Conference y en CPHI.
Defence informó haber completado estudios preclínicos que muestran que el Kadcyla conjugado con Accum produce ~una eficacia antitumoral unas 20 veces mayor que Kadcyla solo, a la misma dosis de 0.5 mg/kg en xenoinjertos de ratón JIMT-1 HER2+, con una respuesta casi completa en el 90% de los ratones.
La empresa está buscando socios de ADC para licenciar o suministrar Accum con el fin de mejorar la potencia y reducir la toxicidad en los programas de ADC.
Defence Therapeutics (OTCQB: DTCFF)는 World ADC Conference 및 CPHI에서 발표한 후 독점 Accum 약물전달 플랫폼을 항체-약물 접합체(ADC) 개발자들에게 공급하는 전략적 전환을 발표했다.
Defence는 Accum-접합 Kadcyla가 같은 0.5 mg/kg 용량에서 Kadcyla 단독보다 ~암 억제 효과가 20배 더 높다는 전임상 연구를 완료했다고 보고했으며, JIMT-1 HER2+ 마우스 이식 종양에서 90%의 생쥐에서 거의 완전 반응을 보였다.
회사는 ADC 프로그램 전반에서 효능을 개선하고 독성을 줄이기 위해 Accum을 라이선스하거나 공급할 ADC 파트너를 모집 중이다.
Defence Therapeutics (OTCQB: DTCFF) a annoncé un tournant stratégique consistant à fournir sa plateforme propriétaire Accum de délivrance de médicaments aux développeurs de conjugués anticorps-médicament (ADC) après sa présentation à la World ADC Conference et au CPHI.
Defence a déclaré avoir terminé des études précliniques montrant que la Kadcyla conjuguée à Accum produisait ~une efficacité antitumorale environ 20 fois supérieure à Kadcyla seul à la même dose de 0,5 mg/kg dans des xénogreffes JIMT-1 HER2+, avec une réponse quasi complète chez 90% des souris.
L'entreprise s'engage auprès de partenaires ADC pour licencier ou approvisionner Accum afin d'améliorer la puissance et de réduire la toxicité dans les programmes ADC.
Defence Therapeutics (OTCQB: DTCFF) kündigte eine strategische Neuausrichtung an, um seine proprietäre Accum-Plattform zur Wirkstoffabgabe an Antikörper-Wirkstoff-Conjugates (ADC) Entwicklern zu liefern, nachdem es auf der World ADC Conference und der CPHI vorgestellt hatte.
Defence berichtete, präklinische Studien hätten gezeigt, dass Accum-gekoppelte Kadcyla eine ~um 20-fach höhere antitumorale Wirksamkeit als Kadcyla allein bei derselben Dosis von 0,5 mg/kg in JIMT-1 HER2+ Maus-Xenograft-Modellen erzeugten, mit einer nahezu vollständigen Reaktion bei 90% der Mäuse.
Das Unternehmen arbeitet mit ADC-Partnern zusammen, um Accum zu lizenzieren oder für Verbesserungen der Potenz und Reduktion von Toxizität in ADC-Programmen bereitzustellen.
Defence Therapeutics (OTCQB: DTCFF) أعلنت عن تحول إستراتيجي لتزويد منصتها الحصرية Accum لإيصال الدواء لمطوري مركبات مضاد الجسم-الدواء (ADC) بعد عرضها في مؤتمر World ADC Conference و CPHI.
ذكرت Defence أنها أكملت دراسات ما قبل السريرية التي أظهرت أن Kadcyla المرتبط بـAccum أدى إلى ~فعالية مضادّة للأورام أعلى بنحو 20 مرة من Kadcyla وحده عند نفس الجرعة 0.5 mg/kg في نماذج فئران JIMT-1 HER2+، مع استجابة شبه كاملة في 90% من الفئران.
الشركة تتعامل مع شركاء ADC للترخيص أو تزويد Accum لتحسين الفاعلية وتقليل السمية عبر برامج ADC.
- Preclinical efficacy: ~20‑fold higher anti‑tumor effect reported
- High response rate: near‑complete response in 90% of treated mice
- Platform applicability: positioned to work with any antibody or indication
- No clinical/human data disclosed; results limited to mouse models
- No binding partnerships or commercial agreements announced
Montreal, Quebec--(Newsfile Corp. - November 19, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a leading biotechnology company pioneering next-generation antibody-drug conjugate ("ADC"), is pleased to announce a major step forward in the fight against cancer that goes beyond the ADCs current limitations.
Following successful presentations and meetings at the World ADC Conference in San Diego with ADC companies as well as with industry leaders and pioneers at CPHI in Frankfurt, Defence is moving forward with the strategy to become a supplier of its Accum® platform technology to ADC companies struggling with dosing and toxicity as well as to improve the drug delivery precision to cancer cells more effectively for the benefit of cancer patients.
"Many pharmaceuticals and biotech companies have ADCs on the market or in development. A lot of these companies are facing the same challenge, their ADC being toxic for the patients at therapeutic dose. Defence's Accum® technology can universally enhance the potency of any ADCs, reducing their toxicity, while retaining their epitope selectivity and tumor targeting," said Dr. Maxime Parisotto, Chief Scientific Officer at Defence Therapeutics.
Defence has completed studies confirming its ability to enhance ADCs potency. The most recent comparative study, in mouse xenograft models of HER2-positive breast cancer (JIMT-1 cells), demonstrated a ~20-fold higher anti-tumor efficacy with Accum®-Kadcyla than Kadcyla® alone when administered at the same dose (0.5 mg/kg). The tumor growth significantly halted in the Accum®-Kadcyla-treated group, resulting in a consistent and near-complete response in
Defence is engaging with ADC companies to transform the ADC cancer therapies with its unique proprietary Accum® technology platform to be used with any antibodies and on any indications. Defence's technology and team are in place to deliver the strategy and build an ADC drug delivery powerhouse.
About Defence:
Defence Therapeutics is a publicly-traded biotechnology company developing and engineering the next generation of ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUM® technology, which enables precision delivery of ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against cancer.
For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272
Splouffe@defencetherapeutics.com
www.defencetherapeutics.com
Cautionary Statement Regarding "Forward-Looking" Information
This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.
Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275070
FAQ
What did Defence Therapeutics (DTCFF) announce on November 19, 2025 about Accum?
What were the key preclinical results for Accum‑Kadcyla reported by Defence (DTCFF)?
Does Defence Therapeutics (DTCFF) have clinical data supporting Accum in humans?
How does Defence plan to commercialize Accum according to the November 19, 2025 release?
Will Accum work with existing ADCs like Kadcyla according to Defence (DTCFF)?
